Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.90 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.90 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL16752517 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL363366 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL612484 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL8557756 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL793773 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL793772 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL10796092 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL7337222 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL12474192 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL363367 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114702659-A | Rosin-based defoaming agent for cleaning electronic devices and preparation method thereof | 江苏斯德瑞克化工有限公司 | 2022-07-05 | — | — | CN | claimed |
| WO-2007120924-A1 | PREPARATION OF TEGASEROD MALEATE FREE OF IODIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-25 | — | — | WO | claimed |
| EP-0369685-B1 | Fluoxetine analog | LILLY CO ELI (US) | 1995-04-19 | — | — | EP | claimed |
| EP-0369685-A2 | Fluoxetine analog | ELI LILLY AND COMPANY (US) | 1990-05-23 | — | — | EP | claimed |
| CN-114702659-A | Rosin-based defoaming agent for cleaning electronic devices and preparation method thereof | 江苏斯德瑞克化工有限公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-1893195-A2 | POLYMORPHIC FORMS OF TEGASEROD MALEATE | Teva Pharmaceutical Industries Ltd (IL) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002314-A9 | POLYMORPHIC FORMS OF TEGASEROD MALEATE | TEVA PHARMA (IL) | 2007-08-23 | — | — | WO | disclosed |
| EP-1771414-A1 | AMORPHOUS TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-11 | — | — | EP | disclosed |
| EP-1740539-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007002314-A2 | POLYMORPHIC FORMS OF TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-01-04 | — | — | WO | disclosed |
| US-20060258633-A1 | Amorphous tegaserod maleate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-11-16 | — | — | US | disclosed |
| WO-2006096802-A1 | AMORPHOUS TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-09-14 | — | — | WO | disclosed |
| WO-2005105740-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
| EP-0369685-B1 | Fluoxetine analog | LILLY CO ELI (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5250571-A | Administering to mammals | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0369685-A2 | Fluoxetine analog | ELI LILLY AND COMPANY (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0300688-A1 | Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them | FISONS plc (GB) | 1989-01-25 | — | — | EP | disclosed |
| US-4243805-A | 3 Fluoro-10-piperazino-8-substituted 10,11-dihydrodibenzo-(bf) thiepins and method for the preparation thereof | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258633-A1 | Amorphous tegaserod maleate | SI, MLNR, SLC10A2 | TSHR 1153/4885TP53 3990/4885EGLN1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.